GR3003615T3 - - Google Patents

Info

Publication number
GR3003615T3
GR3003615T3 GR920400057T GR920400057T GR3003615T3 GR 3003615 T3 GR3003615 T3 GR 3003615T3 GR 920400057 T GR920400057 T GR 920400057T GR 920400057 T GR920400057 T GR 920400057T GR 3003615 T3 GR3003615 T3 GR 3003615T3
Authority
GR
Greece
Application number
GR920400057T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3003615T3 publication Critical patent/GR3003615T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR920400057T 1988-05-30 1992-01-22 GR3003615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13226288 1988-05-30
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Publications (1)

Publication Number Publication Date
GR3003615T3 true GR3003615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-16

Family

ID=26390939

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400057T GR3003615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-05-30 1992-01-22

Country Status (8)

Country Link
US (1) US4983593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0344603B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2528706B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1332152C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE68900356D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2051920T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3003615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ229309A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
ATE223722T1 (de) * 1996-03-18 2002-09-15 Nissan Chemical Ind Ltd Verfahren zur herstellung von efonidipinhaltigen arzneimitteln
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ATE391495T1 (de) * 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
CA2395129C (en) * 1999-12-20 2008-12-16 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
WO2001047495A1 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8207232B2 (en) 2004-05-28 2012-06-26 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1829549A1 (en) * 2004-12-17 2007-09-05 Ono Pharmaceutical Co., Ltd. Amorphous composition
EP1923051A4 (en) * 2005-09-06 2012-12-19 Astellas Pharma Inc MICROPARTICLES OF A HEAVY-DUTY SUBSTANCE WITH ENTERIAN BASE MATERIAL ADSORBED ON THE SUBSTANCE SURFACE
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009038112A1 (ja) 2007-09-21 2009-03-26 Shionogi & Co., Ltd. Npyy5受容体拮抗剤を含有する固形製剤
JPWO2009072334A1 (ja) * 2007-12-03 2011-04-21 富田製薬株式会社 製剤用核粒子
US20110065800A1 (en) * 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2801712A1 (en) 2010-06-14 2011-12-22 Dow Global Technologies Llc Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8591944B2 (en) 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
KR20160104709A (ko) 2013-12-31 2016-09-05 아센디아 파마슈티컬스, 엘엘씨 난수용성 화합물용 약제학적 조성물
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
PT3985002T (pt) 2017-03-01 2025-08-29 Achillion Pharmaceuticals Inc Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos
US20190030003A1 (en) * 2017-03-21 2019-01-31 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CN113365617A (zh) 2018-10-16 2021-09-07 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
CN119837855A (zh) 2019-12-19 2025-04-18 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810A (ja) 1982-09-10 1984-03-21 Sony Corp 磁性記録体におけるデ−タのマスク及び再生方法
JPS62123117A (ja) 1985-11-22 1987-06-04 Nippon Chemiphar Co Ltd 塩酸ニカルジピン経口用組成物
CN1016063B (zh) * 1986-01-22 1992-04-01 日产化学工业株式会社 二氢吡啶-5-膦酸环亚丙基酯的制备
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
CA1332152C (en) 1994-09-27
NZ229309A (en) 1991-06-25
EP0344603B1 (en) 1991-10-23
EP0344603A1 (en) 1989-12-06
JP2528706B2 (ja) 1996-08-28
JPH0249728A (ja) 1990-02-20
ES2051920T3 (es) 1994-07-01
DE68900356D1 (de) 1991-11-28
US4983593A (en) 1991-01-08

Similar Documents

Publication Publication Date Title
GR3003615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN172123B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT9021541A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2625936B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2626860B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2639319B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2638047B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2628792B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2626951B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2630172B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2628215B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0764674A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR3012794T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7928591A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2626669B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2626876B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7949087A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU8195787A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7885487A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7773787A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR2000251Y (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU1767888A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR2000304Y (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU1169888A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN171958B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)